Abstract:Aim: Prescription drug prices in the United States are considered rather extreme. Americans spend over $460 billion on drugs annually, or almost 17 percent of total national healthcare spending. How innovation incentives and insurance coverage drive pricing, diffusion, and utilization of drugs, under conditions of risk and competition, are multi-dimensional issues in medical economics that remain under-explored in the current empirical literature. We seek to address these issues in reviewing relevant studies presented at the 2020 AEA-ASSA annual convention. Approach: Drawn from the 2020 convention panel sessions devoted to health economics, empirical evidence was thematically analyzed for charted new research terrains and trajectories. Their theoretical and practical implications on efficiency, effectiveness, and value in drug production and consumption were then identified. Findings: With certain qualifications, evidence confirms price inelasticity of prescription drugs and medical treatments, along with substitution effects from high or continuously rising prices. While health insurance induces ex ante moral hazard, albeit on a larger scale than previously considered, losing dependent coverage can incentivize price-substitution to risky and illegal drugs, including those sold on the black market. At the firm level, drug patenting and exclusivity rights suggest that innovation incentives increase new or novel clinical trials and generic utilization to a considerable extent. But innovation can produce strong, offsetting effects. It can distort competition and cause (at times sharp) price increases from product-hopping, (compensatory) list pricing, industry mergers and acquisitions, and capture of positive spillovers by competitors, rather than by focal developers, in follow-on innovations. In fine, there remains room for opportunism among firms, particularly market incumbents, and many loopholes are unplugged by U.S. healthcare reform. These make drug utilization costly to the insured, and risky to those who are - or become - uninsured or underinsured for various reasons. Conclusions: The fundamental disconnect between innovation cost and drug pricing demands public attention and policy intervention, which have proved largely elusive to date. Gaming the system in the name of scientific invention and discovery to reap additional benefits, at the expense of consumer health and income, brings to question the offsetting benefits of firm innovation. It also raises separate issues of fairness and equity. Innovation needs to be considered from the perspective of value lines and beyond conventional marketing incentives to drug utilization, with or without insurance coverage. Cost-effectiveness and cost-benefit analyses figure prominently under a value-based system of resource allocation, insurance, medical prescription, purchasing, and reimbursement.

Choosing Drugs on Price Alone Will Stifle Innovation, Says Report

NICE Uses Wrong Comparator to Assess Cost Effectiveness of New Drugs, Report Says.

Nice Sets Cap On Drugs Costing More Than 20m Pound

NICE is Too Generous in Approving Drugs, Analysis Says.

Speeding Up Access to New Drugs Threatens Evidence Based Medicine, Says Health Economist

Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks

Timely, Cheap, or Risk-Free? The Effect of Regulation on the Price and Availability of New Drugs

Reliably Assessing "Value" While Addressing High Prices

Escalating costs of innovative medicines: perspective and proposals

Nhs Must Find Ways To Speed Access To New Drugs And Technologies

Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required

Question-based drug development and the value of novel treatments

Pharmaceutical pricing in Europe: time to take the right direction

When the price is right: drug costing and NICE approval.

Fairness in the trade-off between drug price regulation and investments in research and development: A survey of economists

NICE to Advise Firms on How to Speed Up NHS Adoption of Their Drugs

Pricing, profits and pharmacoeconomics--for whose benefit?

Why are our medicines so expensive? Spoiler: Not for the reasons you are being told...

Cancer Drugs Fund Receives Boost but Will No Longer Fund “overpriced” Drugs

Incentives and disincentives to drug innovation: evidence from recent literature

Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics